drugset / Trial / NCT01324544

Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain

NCT01324544

Phase 3 Withdrawn Purdue Pharma LP
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the safety, pharmacokinetics (PK), and efficacy of intravenous (IV) buprenorphine in pediatric patients.

Timeline

Start
2011-11
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified Intravenous

Indications

No indication recorded.